Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01238666 · ClinicalTrials.gov registry record
Evaluation of a Minimally Invasive Image-Guided Surgery System for Hepatic Ablation Procedures
A clinical trial of Liver Cancer, sponsored by Pathfinder Therapeutics.
- Completed
- Registry status
- 27
- Enrollment target
- 1
- Study location
NCT01238666 is a study of Liver Cancer that has completed, run by Pathfinder Therapeutics. The registered enrollment target is 27 participants, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01238666, a study of Liver Cancer, has completed, sponsored by Pathfinder Therapeutics.
- COMPLETED
- Registry status
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
This study was designed in two phases: Phase I is designed to confirm that the surgeon is able to perform accurate liver surface registration including standard liver features used as landmarks during a scheduled laparoscopic liver ablation procedure and acquires a level of comfort with the procedure. The surface of the liver will be manually swabbed with the study tracked laparoscopic probe with landmarks noted during data collection. After registration of the liver is obtained, the registration points obtained during this procedure will be evaluated by the surgeon by moving the tracked laparoscopic probe over the liver surface and evaluating the location of the tracked laparoscopic probe displayed on the guidance system three dimensional (3D) image. The surgeon will accept or reject the registration accuracy. The hypothesis is that the surgeon will be able to successfully acquire liver surface registrations with a small learning curve for technique and will be able to proceed to Phase II of the study. Phase II contains the registration process included above but adds the additional process of tracking the ablation probe used to perform tumor ablation by attaching the Pathfinder Multi-Tool adaptor and collecting data showing the location of the ablation probe as tracked and displayed on the Pathfinder three dimensional (3D) image. The surgeon will use ultrasound (US) guidance to locate tumor location during the laparoscopic procedure. The images collected during this process will be recorded by Pathfinder.
Conditions Studied
Study Locations (1)
Oregon
- Providence Portland Medical Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-11 |
| Est. Completion | 2012-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01238666
The ClinicalTrials.gov registry entry for NCT01238666 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Pathfinder Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Liver Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT01238666 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT01238666 about?
NCT01238666 is a clinical study titled "Evaluation of a Minimally Invasive Image-Guided Surgery System for Hepatic Ablation Procedures". This study was designed in two phases: Phase I is designed to confirm that the surgeon is able to perform accurate liver surface registration including standard liver features used as landmarks during a scheduled laparoscopic liver ablation procedure and acquires a level of comfort with the procedur...
What is the current status of trial NCT01238666?
This trial is currently completed. The enrollment target is 27 participants. The study started on 2010-11. Estimated completion is 2012-03.
What conditions does trial NCT01238666 study?
This clinical trial studies the following conditions: Liver Cancer.
Who is sponsoring clinical trial NCT01238666?
This trial is sponsored by Pathfinder Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01238666 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Feasibility Study of CBCT for IGRT in Cancer Patients
RECRUITING · NA
-
Collection of Blood From Patients With Cancer
RECRUITING
-
National Liver Cancer Screening Trial
RECRUITING · Phase 4
-
vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC
RECRUITING · NA
-
Multi-analyte Blood Test Clinical Trial
RECRUITING
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.